Table 1.
Characteristics of included studies.
| First author, year | Country | Study design | Centers | Sample size (pre/post) | Follow-up | Main outcomes | NOS score |
|---|---|---|---|---|---|---|---|
| Callender 2017 (5) | USA | Retrospective cohort | Single | 57/18 | 1 year | Graft loss, complications | 8 |
| Jeon 2012 (23) | Korea | Retrospective cohort | Multicenter | 37/63 | 5 years | eGFR, THPT | 7 |
| Littbarski 2018 (short-term) (22) | Germany | Retrospective cohort | Single | 52/14 | 1 year | KDIGO stage, eGFR | 8 |
| Littbarski 2018 (long-term) (22) | Germany | Retrospective cohort | Single | 67/56 | 7 years | KDIGO stage, eGFR | 8 |
| Oruc 2021 (24) | Turkey | Retrospective cohort | Single | 12/15 | ~5 years | Graft loss, DGF, eGFR | 6 |
| van der Plas 2019 (25) | Netherlands | Retrospective cohort | Multicenter | 102/83 | 5 years | eGFR, complications | 8 |
| Okada 2019 (26) | Japan | Retrospective cohort | Single | 55/53 | ~5 years | eGFR, hypocalcemia | 8 |
| Wang 2023 (27) | USA | Retrospective cohort | Single | 23/75 | 5 years | Graft loss, DGF, Cr | 8 |
| Foote 2025 (28) | USA | Retrospective cohort | Multicenter | 1,972/541 | 30 days | 30-day morbidity, MACE, readmission | 9 |